FDA: No oral ketoconazole for skin, nail fungus
The Food and Drug Administration is warning health care professionals not to prescribe oral ketoconazole for patients with fungal infections of the skin and nails, because of "the risks of serious liver damage, adrenal gland problems, and harmful interactions with other medicines that... (Source: Skin and Allergy News)
Source: Skin and Allergy News - May 19, 2016 Category: Dermatology Source Type: news
FDA Drug Safety Communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death
[05-19-2016] The U.S. Food and Drug Administration (FDA) is warning health care professionals to avoid prescribing the antifungal medicine ketoconazole oral tablets to treat skin and nail fungal infections. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 19, 2016 Category: Drugs & Pharmacology Source Type: news
What Women Can Do About Hair Loss
SPECIAL FROM Next Avenue By Sheryl Kraft Everyone loses hair. In fact, it’s normal to lose between 50 and 100 hairs a day, according to the American Academy of Dermatology. But what if it seems like there’s significantly more loss than that? “Once you exceed that, you’re losing it at an abnormal rate,” says Dr. David J. Wong, clinical associate professor of dermatology at Stanford University. Contrary to popular notion, hair loss is not just a condition that men face: up to 40 percent of women in America also experience it. No ‘Bald Is Beautiful’ for Women Bruce Willis, Patri...
Source: Healthy Living - The Huffington Post - October 20, 2015 Category: Consumer Health News Source Type: news
EU Looks to Okay Ketoconazole for Use in Cushing's SyndromeEU Looks to Okay Ketoconazole for Use in Cushing's Syndrome
Patients with Cushing's syndrome are close to gaining access to ketoconazole in the European Union, following the EMA's decision to recommend approval of the agent for this condition. International Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 26, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
Differential diagnosis of Cushing’s syndrome
Factitious Cushing’s syndrome is extremely rare. The diagnosis is challenging as cross-reactivity of synthetic corticosteroids or their metabolites in immunoassay measurements of plasma or urinary cortisol can make distinguishing between true and factitious Cushing’s syndrome difficult.
Thynne et al. report on a case of a 54-year old woman who presented with clinical and biochemical features of Cushing’s syndrome and an unsuppressed ACTH concentration. They show that the key to the diagnosis of factitious Cushing’s syndrome in their patient was the recognition of the disc...
Source: Society for Endocrinology - March 12, 2014 Category: Endocrinology Source Type: news
Oral Ketoconazole in Dermatology: Where Are We Now?Oral Ketoconazole in Dermatology: Where Are We Now?
What does the recent Drug Safety Communication on ketoconazole mean for dermatology practice? Medscape Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2013 Category: Consumer Health News Tags: Dermatology Commentary Source Type: news
Increased Sample Throughput For Ketoconazole Analysis By Automated 96-Well Sample Preparation And Multiplexed HPLC
In order to increase the sample throughput of a manual LC-FL assayfor ketoconazole, the method was automated and a multiplexed HPLC system wasemployed.By K. Szczap, C. Loop, D. Gray, H. Freiser, R. Shoup, and A. Witkowski (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - August 23, 2013 Category: Pharmaceuticals Source Type: news
FDA Puts Strict Limits on Oral Ketoconazole Use
(MedPage Today) -- SILVER SPRING, Md. -- Oral ketoconazole (Nizoral) should never be used as first-line therapy for any fungal infection because of the risk of liver toxicity and interactions with other drugs, the FDA said Friday. (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - July 26, 2013 Category: Infectious Diseases Source Type: news
FDA, EMA Come Down Hard on Oral KetoconazoleFDA, EMA Come Down Hard on Oral Ketoconazole
The EMA recommends pulling the antifungal tablets from the markets; the FDA says clinicians should drop them as a first-line therapy because of the risk for severe liver injury and other problems. News Alerts (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - July 26, 2013 Category: Infectious Diseases Tags: Infectious Diseases News Alert Source Type: news
Nizoral (ketoconazole): Drug Safety Communication - Potentially Fatal Liver Injury, Risk of Drug Interactions and Adrenal Gland Problems
Nizoral tablets should be used only for the treatment of certain life-threatening mycoses when the potential benefits outweigh the risks, and alternative therapeutic options are not available or tolerated. (Source: FDA MedWatch)
Source: FDA MedWatch - July 26, 2013 Category: American Health Source Type: news
ketoconazole, Nizoral, Extina, Xolegel, Kuric
Title: ketoconazole, Nizoral, Extina, Xolegel, KuricCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 4/1/2013 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - April 1, 2013 Category: Dermatology Source Type: news
